In England, national guidelines specify that all women with newly diagnosed high-grade ovarian cancer undergo tumour testing for BRCA1/2 pathogenic/likely pathogenic variants and homologous recombination deficiency (HRD). This evidence concerns the gene BRCA1 and neoplasm.